High mRNA expression of CCL17, CCL22, CCR4, and Foxp3 was detected in 5.0%, 3.0%, 2.2%, and 5.0% of patients with prostate cancer, respectively (figure 5A). The gene discussed is FOXP3; the disease is prostate carcinoma.